A federal judge has vacated a $140 million verdict over “low testosterone” treatments after finding that the jury’s findings were inconsistent.
The Oct. 5 verdict was the second bellwether award to come out of multidistrict litigation alleging AbbVie Inc. and other companies misrepresented the safety of their topical gels used to treat low testosterone in aging men. About 6,000 lawsuits have alleged the treatments caused heart attacks and blood clots.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
